Effect of Candesartan on Creatinine and Albuminuria in Geriatric Patients with Diabetic Nephropathy

Authors

  • Luh Gede Sri Yenny Faculty of Medicine and Health Sciences, Warmadewa University
  • Ni Wayan Rusni Faculty of Medicine, Warmadewa University

Keywords:

candesartan, creatinine, proteinuria, diabetic, nephropathy

Abstract

Diabetes can cause various chronic complications, one of the most feared being diabetic nephropathy. Diabetic nephropathy is characterized by proteinuria and/or decreased glomerular filtration rate. Diabetic nephropathy is a major cause of chronic kidney disease, which can lead to end-stage renal disease requiring hemodialysis. Candesartan is an angiotensin receptor blocker antihypertensive drug. In addition to lowering blood pressure, candesartan is also thought to decrease renal vascular resistance, resulting in a decrease in microalbuminuria or proteinuria in patients with diabetes mellitus. Diabetic nephropathy increases with age, and geriatric patients have a lower response to therapy than adults. To determine the effect of candesartan on creatinine and albuminuria in geriatric patients with diabetic nephropathy. This was a cross-sectional study of 25 geriatric patients diagnosed with diabetic nephropathy who had been given 16 mg of candesartan as an antihypertensive at the Puri Raharja Hospital Denpasar outpatient clinic. Subjects who met the inclusion and exclusion criteria were recruited using consecutive sampling. The diabetic nephropathy subjects were evaluated for creatinine and proteinuria levels at the time of diagnosis and 3 months after receiving 16 mg of candesartan. All data were obtained from medical records. The study involved 25 patients consisting of 13 men (52%) and 12 women (485%). Subjects aged between 60-82 years with initial creatinine levels of 0.80-2.60 mg/dL, final creatinine levels of 1.395 ± 0.50 SD, initial positive proteinuria levels of 0-2, and final positive creatinine levels of 0-1. Based on the T-test, there was no significant difference between initial and final creatinine levels with a p value = 0.892 (95% CI -0.045-0.051). Based on the Wilcoxon test, there was a significant difference between proteinuria levels before and after candesartan administration with a p value p <0.05. This study did not find a significant decrease in creatinine after candesartan administration. However, candesartan significantly reduced proteinuria in geriatric patients with diabetic nephropathy.

References

Mezil SA, Abed BA. Complication of Diabetes Mellitus. Annals of R.S.C.B. 2021; 25 (3): 1546 – 1556.

American Diabetes Association. Chronic kidney disease and risk management: Standards of medical care in diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S219-30.

John S. Complication in diabetic nephropathy. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2016;4: 247-249.

Hoshino J, Muenz D, Zee J, Rayner S, Budhwar S, Vakani H, et al. Associations of candesartan with proteinuria and renal outcomes in patients with type 2 diabetes: a real-world evidence study. Clin Exp Nephrol. 2023;27(4):315-24.

Kuwabara S, Gidoh S, Kasai S. Long-term effects of candesartan on proteinuria and renal function in diabetic patients with chronic kidney disease: a 10-year follow-up. Kidney Res Clin Pract. 2020;39(2):185-94.

Tatsumi R, Miyagi S, Kaneto H. Impact of candesartan on urinary albumin excretion and intrarenal hemodynamic parameters in diabetic nephropathy. Diabetol Int. 2019;10(3):210-6. Persson F, Lindhardt M, Rossing P. The role of candesartan in the prevention of diabetic nephropathy: an update on recent clinical evidence. Curr Diab Rep. 2016;16(5):45.

Zhang Y, He X, Soman S, Li J. Efficacy of angiotensin receptor blockers on albuminuria in patients with diabetic nephropathy: a systematic review and meta-analysis of randomized controlled trials. J Diabetes Res. 2022;2022:8841203.

Horwitz EJ,Schelling JR. Treatment of albuminuria due to diabetic nephropathy: recent trial results.Clin. Invest.2014; 4(4): 327–34.

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953-2041.

Downloads

Published

2025-12-30

How to Cite

Sri Yenny, L. G., & Ni Wayan Rusni. (2025). Effect of Candesartan on Creatinine and Albuminuria in Geriatric Patients with Diabetic Nephropathy. Jurnal EduHealth, 16(04), 1969–1973. Retrieved from https://ejournal.seaninstitute.or.id/index.php/healt/article/view/7972